Aptamer Group plc announces that Dr. Arron Tolley has left his position as Chief Executive Officer and Board Director, with immediate effect. He will leave his employment with the Group after a period of garden leave. As a consequence, current Chief Financial Officer, Dr. Rob Quinn, will now also assume the role of interim CEO.

A search for a full-time CEO will begin immediately. Rob Quinn is an experienced life sciences executive with highly relevant scientific experience working with publicly listed biotechnology and pharmaceutical companies, including as CFO of Silence Therapeutics.